These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34560927)

  • 21. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
    Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E
    J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.
    Melamed JR; Ioele SA; Hannum AJ; Ullman VM; Day ES
    Mol Pharm; 2018 Nov; 15(11):5135-5145. PubMed ID: 30260647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
    Boiardi A; Silvani A; Eoli M; Lamperti E; Salmaggi A; Gaviani P; Fiumani A; Botturi A; Falcone C; Solari A; Filippini G; Di Meco F; Broggi G
    J Neurooncol; 2008 May; 88(1):105-13. PubMed ID: 18283418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temozolomide for high grade glioma.
    Hart MG; Garside R; Rogers G; Stein K; Grant R
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report.
    Okita Y; Nonaka M; Umehara T; Kanemura Y; Kodama Y; Mano M; Nakajima S
    Oncol Lett; 2015 Apr; 9(4):1885-1888. PubMed ID: 25789061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
    Chua SL; Rosenthal MA; Wong SS; Ashley DM; Woods AM; Dowling A; Cher LM
    Neuro Oncol; 2004 Jan; 6(1):38-43. PubMed ID: 14769139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
    Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
    Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
    Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].
    Sun W; Zou X; Zhang W; Hu S; Ge K
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Feb; 41(2):250-255. PubMed ID: 33624599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
    J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis.
    Malik D
    Clin Nucl Med; 2021 Feb; 46(2):138-139. PubMed ID: 33234937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
    Chinot OL; Barrie M; Frauger E; Dufour H; Figarella-Branger D; Palmari J; Braguer D; Hoang-Xuan K; Moktari K; Peragut JC; Martin PM; Grisoli F
    Cancer; 2004 May; 100(10):2208-14. PubMed ID: 15139066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
    Kong X; Wang Y; Liu S; Chen K; Zhou Q; Yan C; He H; Gao J; Guan J; Yang Y; Li Y; Xing B; Wang R; Ma W
    Medicine (Baltimore); 2015 Jun; 94(24):e962. PubMed ID: 26091464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
    Gerstner ER; Emblem KE; Chang K; Vakulenko-Lagun B; Yen YF; Beers AL; Dietrich J; Plotkin SR; Catana C; Hooker JM; Duda DG; Rosen B; Kalpathy-Cramer J; Jain RK; Batchelor T
    Clin Cancer Res; 2020 Jan; 26(1):206-212. PubMed ID: 31558474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
    Ngo MT; Harley BAC
    Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.